Abstracts tagged "randomized trials and rheumatic disease"

Abstract Number: 841 • 2017 ACR/ARHP Annual Meeting
Optimal Regimens of Sulfamethoxazole-Trimethoprim for Chemoprophylaxis of Pneumocystis Pneumonia in Patients with Systemic Rheumatic Diseases: 52-Week Follow-up of a Non-Blinded, Randomized Controlled Trial
Masayoshi Harigai^1,2, Masako Utsunomiya^2,3,4, Hiroaki Dobashi⁵, Toshio Odani^6,7, Kazuyoshi Saito^8,9, Naoto Yokogawa¹⁰, Kenji Nagasaka^11,12, Kenchi Takenaka^3,11, Makoto Soejima^11,13, Takahiko Sugihara¹⁴, Hiroyuki Hagiyama¹⁵, Shinya Hirata¹⁶, Kazuo Matsui^17,18, Yoshinori Nonomura¹⁹, Masahiro Kondo²⁰, Fumihito Suzuki^13,21, Makoto Tomita²², Mari Kihara²³, Waka Yokoyama³, Fumio Hirano²⁴, Hayato Yamazaki³, Ryoko Sakai^2,25, Toshihiro Nanki^2,26, Ryuji Koike^2,3, Hitoshi Kohsaka³ and Nobuyuki Miyasaka³, ¹Division of Epidemiology and Pharmacoepidemiology of Rheumatic Diseases, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Department of Pharmacovigilance, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan, ³Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan, ⁴Department of Rheumatology, Musashino Red Cross Hospital, Tokyo, Japan, ⁵Internal Medicine Division of Hematology, Rheumatology, and Respiratory Medicine, Kagawa University, Kagawa, Japan, ⁶Third Department of Internal Medicine, Obihiro-Kosei General Hospital, Hokkaido, Japan, ⁷Molecular Physiology and Therapeutics Branch/Adeno-Associated Virus Biology Section, National Institute of Dental and Craniofacial Research (NIDCR)/ National Institutes of Health (NIH), Bethesda, MD, ⁸Tobata General Hospital, Fukuoka, Japan, ⁹The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ¹⁰Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan, ¹¹Department of Rheumatology, Ome Municipal General Hospital, Tokyo, Japan, ¹²Department of Pharmacovigilance, Graduate School of Medical and Dental Sciences,, Tokyo Medical and Dental University, Tokyo, Japan, ¹³Department of Rheumatology, Soka Municipal Hospital, Saitama, Japan, ¹⁴Department of Medicine and Rheumatology, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan, ¹⁵Department of Rheumatology, Yokohama City Minato Red Cross Hospital, Kanagawa, Japan, ¹⁶Department of Hematology, Rheumatology, and Infectious Disease, Kumamoto University, Kumamoto, Japan, ¹⁷Department of Rheumatology, Kameda Medical Center, Chiba, Japan, ¹⁸Department of Internal Medicine, Takikawa Municipal Hospital, Hokkaido, Japan, ¹⁹Department of Rheumatology, Tokyo Kyosai Hospital, Tokyo, Japan, ²⁰Department of Rheumatology, Faculty of Medicine, Shimane University, Shimane, Japan, ²¹Department of Rheumatology, JA Toride Medical Center, Ibaraki, Japan, ²²Clinical Research Center, Tokyo Medical and Dental University, Tokyo, Japan, ²³Department of Rheumatology, Tokyo Medical and Dental University, Tokyo, Japan, ²⁴Departments of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan, ²⁵Division of Epidemiology and Pharmacoepidemiology of Rheumatic Diseases, Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, ²⁶Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Tokyo, Japan
Background/Purpose: Sulfamethoxazole-trimethoprim (SMX/TMP) is a standard drug for the prophylaxis of Pneumocystis pneumonia (PCP), but is sometimes discontinued due to adverse events (AEs). We have…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].